Prescription and self-medication patterns in the general population of Ecuador during the COVID-19 pandemic. A Cross-sectional study.
Main Article Content
Keywords
COVID-19, Medication Therapy Management, Treatment Adherence and Compliance, Prevalence, SARS-CoV-2, Patient Compliance
Abstract
Background: The SARS-CoV-2 pandemic affected over 200 million people worldwide, with Ecuador being one of the hardest-hit countries in the Andean region, reporting approximately 777 thousand cases. Despite treatment strategies for COVID-19, various medication groups not recommended for mild to moderate cases were widely consumed by the population. This study aimed to determine the medication patterns of consumption in the general population of Ecuador during the COVID-19 pandemic. Methodology: Cross-sectional study with a sample of 410 participants, calculated with an expected proportion of 36.8% from the Quisphe-Cañari study, a confidence level of 95%, and a precision of 5%. Non-probabilistic sampling was applied, with inclusion criteria as Ecuador residents over 18 years old and exclusion criteria excluding pregnant women. The dependent variable was “medication consumption.” Independent variables included age, gender, marital status, educational level, employment status, economic income, self-medication, and type of medication consumed. Exploratory data analysis, descriptive statistics, and frequency tables were applied for each variable. Medication consumption frequency was estimated, considering individuals using any medication as the numerator and the entire surveyed population as the denominator. SPSS26 software was used. Results: 410 participants, with an average age of 31.1±10.7 years, 62.9% were women, and 66.6% were single. 54.1% of participants used pharmacological therapy during the pandemic, with 64.4% having a medical prescription and 35.6% engaging in self-medication. In the self-medication group, analgesics was the most consumed (33.8%), followed by Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) (22.9%), antibiotics (14.9%), and antihistamines (13.9%). In the medical prescription group, the most frequent drugs were analgesics (26.3%), NSAIDs (23.2%), antibiotics (18.5%), and antihistamines (16.9%). Regarding other medication groups, the frequency of corticosteroid consumption was 6.3% and antiparasitic agents with 6.5%. Conclusion: In Ecuador, several medication groups without indication for mild to moderate COVID-19, such as corticosteroids, antibiotics, and antiparasitics, were consumed under medical prescription.
References
2. Ministerio de Salud Pública. Datos epidemiológicos: Casos Covid-19 [Internet]. 2022 [cited 2022 Nov 17]. Available from: https://app.powerbi.com/viewr=eyJrIjoiNjkzNjUyNGMtZjc1NC00OWU0LWEzMWQtOTFkY2ZkYjZkMWIwIiwidCI6IjcwNjIyMGRiLTliMjktNGU5MS1hODI1LTI1NmIwNmQyNjlmMyJ9& pageName=ReportSection33e2bb803a8b183d9100
3. National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. 2023. Available from: https://www.covid19treatmentguidelines.nih.gov/
4. Chahin A, Dhabaan G, Buhaish A, Shorman M. Medications and Supplements Prescription Patterns during COVID 19 Pandemic in Yemen: A Questionnaire-Based Study HHS Public Access. J Health Sci. 2022;5(3):522-8. https://doi.org/10.26502/fjhs.079
5. World Health Organization. Strategy to Achieve Global Covid-19 Vaccination by mid-2022. COVID-19: Scientific briefs. Available in: https://www.who.int/publications/m/item/strategy-to-achieve-global-covid-19-vaccination-by-mid-2022.
6. Clemente-Suárez VJ, Hormeño-Holgado A, Jiménez M, Benitez-Agudelo JC, Navarro-Jiménez E, Perez-Palencia N, et al. Dynamics of Population Immunity Due to the Herd Effect in the COVID-19 Pandemic. Vaccines. 2020;8(2):236. https://doi.org/10.3390/vaccines8020236
7. OPS/OMS. COVID-19. Respuesta de la OPS/OMS Agosto del 2022. Informe N° 81. Informes de situación de la COVID-19. https://www.paho.org/es/documentos/covid-19-respuesta-opsoms-reporte-81-agosto-2022.
8. Quispe-Cañari JF, Fidel-Rosales E, Manrique D, Mascaró-Zan J, Huamán-Castillón KM, Chamorro-Espinoza SE, et al. Selfmedication practices during the COVID-19 pandemic among the adult population in Peru: A cross-sectional survey. Saudi Pharm J. 2021;29(1):1-11. https://doi.org/10.1016/j.jsps.2020.12.001
9. WHO Collaborating Centre Drug Statistics Methodology. ATC/DDD Index [Internet]. 2023 [cited 2023 Jul 29]. Available from: https://www.whocc.no/atc_ddd_index/
10. Asociación Médica Mundial. DECLARACIÓN DE HELSINKI DE LA AMM - PRINCIPIOS ÉTICOS PARA LAS INVESTIGACIONES MÉDICAS EN SERES HUMANOS [Internet]. 2019. Available from: https://www.wma.net/es/policies-post/declaracion-dehelsinki- de-la-amm-principios-eticos-para-las-investigaciones-medicas-en-seres-humanos/
11. Hashem AM, Alghamdi BS, Algaissi AA, Alshehri FS, Bukhari A, Alfaleh MA, et al. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. 2020;35:101735. https://doi.org/10.1016/j.tmaid.2020.101735
12. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery.2020;6(1):1-4. https://doi.org/10.1038/s41421-020-0156-0
13. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020;30(3):269-71. https://doi.org/10.1038/s41422-020-0282-0
14. Younis NK, Zareef RO, Al Hassan SN, Bitar F, Eid AH, Arabi M. Hydroxychloroquine in COVID-19 Patients: Pros and Cons. Frontiers in Pharmacology. Frontiers Media S.A. 2020;11:597985. https://doi.org/10.3389/fphar.2020.597985
15. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine [Internet]. 2020;383(21):2030-40. https://doi.org/10.1056/nejmoa2022926
16. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. New England Journal of Medicine [Internet]. 2021;384(6):497-511. https://doi.org/10.1056/nejmoa2023184
17. WHO. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19 [Internet]. 2020. https://www.who.int/news/item/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-forcovid-19
18. Yang SNY, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res. 2020;177:104760. https://doi.org/10.1016/j.antiviral.2020.104760
19. Kinobe RT, Owens L. A systematic review of experimental evidence for antiviral effects of ivermectin and an in-silico analysis of ivermectin’s possible mode of action against SARS-CoV-2. Fundam Clin Pharmacol [Internet]. 2021;0-3. https://doi.org/10.1111/fcp.12644
20. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. https://doi.org/10.1016/j.antiviral.2020.104787
21. Popp M, Reis S, Schießer S, Hausinger RI, Stegemann M, Metzendorf MI, et al. Ivermectin for preventing and treating COVID-19. Cochrane Database of Systematic Reviews. 2023;35(5):381-3.
22. WHO. Newsroom. 2021 [cited 2023 Aug 11]. WHO advises that ivermectin only be used to treat COVID-19 within clinical trials. Available from: https://www.who.int/news-room/feature-stories/detail/who-advises-that-ivermectin-only-be-used-to-treatcovid-19-within-clinical-trials
23. Khezri MR, Zolbanin NM, Ghasemnejad-berenji M, Jafari R. Azithromycin: Immunomodulatory and antiviral properties for
SARS-CoV-2 infection. Eur J Pharmacol. 2021;905:174191. https://doi.org/10.1016/j.ejphar.2021.174191
24. Butler CC, Dorward J, Yu LM, Gbinigie O, Hayward G, Saville BR, et al. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. The Lancet [Internet]. 2021;397(10279):1063-74. https://doi.org/10.1016/s0140-6736(21)00461-x
25. Hinks TSC, Cureton L, Knight R, Wang A, Cane JL, Barber VS, et al. Azithromycin versus standard care in patients with mild-tomoderate COVID-19 (ATOMIC2): an open-label, randomised trial. Lancet Respir Med [Internet]. 2021;9(10):1130-40. https://doi.org/10.1016/s2213-2600(21)00263-0
26. Popp M, Stegemann M, Riemer M, Metzendorf MI, Romero CS, Mikolajewska A, et al. Antibiotics for the treatment of COVID-19. Cochrane Database of Systematic Reviews. 2021;10(10):CD015025. https://doi.org/10.1002/14651858.cd015025
27. Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine. 2021;384(8):693-704. https://doi.org/10.1056/nejmoa2021436
28. Wagner C, Griesel M, Mikolajewska A, Mueller A, Nothacker M, Kley K, et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database of Systematic Reviews. 2021;8(8):CD014963. https://doi.org/10.1002/14651858.cd014963
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.